FEMSelect is a company headquartered in the United States.
FEMSelect develops EnPlace, a same-day, minimally invasive medical device and procedure for treating pelvic organ prolapse. The EnPlace approach is FDA-cleared, was tested in human trials, and is intended to provide pelvic support with typically no overnight hospital stay.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.